Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ProLectin-M Dose Optimization in Mild to Moderate COVID-19
NCT05733780Phase 2Not yet recruiting
- Sponsor
- BioXyTran, Inc.
- Start
- Sep 2023
- Primary completion
- Dec 2023
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of Prolectin-M in coronavirus disease 2019 (COVID-19), sponsored by BioXyTran, Inc.. Planned start Sep 2023; status: not yet recruiting.
02
Drugs
Prolectin-M
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05733780.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05733780.